Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Cyclo Therapeutics Inc
(NQ:
CYTH
)
1.270
+0.010 (+0.79%)
Streaming Delayed Price
Updated: 10:43 AM EDT, Jun 10, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Cyclo Therapeutics Inc
< Previous
1
2
3
Next >
Cyclo Therapeutics Submits Investigational New Drug Application to U.S. FDA to Advance Trappsol® Cyclo™ in Phase 2 Study for Treatment of Alzheimer’s Disease
November 16, 2021
From
Cyclo Therapeutics, Inc.
Via
Business Wire
Cyclo Therapeutics Provides Business Update and Reports Third Quarter 2021 Financial Results
November 15, 2021
From
Cyclo Therapeutics, Inc.
Via
Business Wire
Cyclo Therapeutics to Present at the Virtual Investor Roundtable Event
November 10, 2021
From
Cyclo Therapeutics, Inc.
Via
Business Wire
JTC Team to Host Virtual Investor Roundtable Event on November 16th, 17th, and 18th
November 04, 2021
- Access the event and schedule of presenting companies at virtualinvestorco.com - - Live video webcast roundtable discussions with members of Management and Thought Leaders across participating...
From
JTC Team, LLC
Via
AccessWire
Cyclo Therapeutics Names Preeminent Neuroscientist and World-Renowned Researcher, Cynthia A. Lemere, PhD, as Senior Advisor for Advancement of Alzheimer’s Disease Asset
November 02, 2021
From
Cyclo Therapeutics, Inc.
Via
Business Wire
Cyclo Therapeutics Recognizes Niemann-Pick Disease Awareness Month Highlighting Need for Broader Awareness and Support for Research to Find a Treatment
October 19, 2021
From
Cyclo Therapeutics, Inc.
Via
Business Wire
Cyclo Therapeutics Announces Abstract Accepted for Poster Presentation at the 14th International Congress of Inborn Errors of Metabolism (ICIEM)
October 18, 2021
From
Cyclo Therapeutics, Inc.
Via
Business Wire
Cyclo Therapeutics to Participate in the 2021 Virtual Cyclodextrin Conference Hosted by CycloLab
October 06, 2021
From
Cyclo Therapeutics, Inc.
Via
Business Wire
Cyclo Therapeutics Appoints Lise Lund Kjems, MD, PhD as Chief Medical Officer
September 27, 2021
From
Cyclo Therapeutics, Inc.
Via
Business Wire
Cyclo Therapeutics to Present at the Oppenheimer Fall Healthcare Life Sciences and MedTech Summit
September 15, 2021
From
Cyclo Therapeutics, Inc.
Via
Business Wire
Cyclo Therapeutics to Present at H.C. Wainwright 23rd Annual Global Investment Conference
September 08, 2021
From
Cyclo Therapeutics, Inc.
Via
Business Wire
Cyclo Therapeutics Provides Business Update and Reports Second Quarter 2021 Financial Results
August 17, 2021
From
Cyclo Therapeutics, Inc.
Via
Business Wire
Cyclo Therapeutics Announces New Positive Safety and Efficacy Data from Ongoing Phase 1 Open-Label Extension Study of Trappsol® Cyclo™ for the Treatment of Niemann-Pick Disease Type C1
July 30, 2021
From
Cyclo Therapeutics, Inc.
Via
Business Wire
Cyclo Therapeutics Commences Commercial-Scale Manufacturing for Trappsol® Cyclo™
July 27, 2021
From
Cyclo Therapeutics, Inc.
Via
Business Wire
Cyclo Therapeutics to Present at the 2021 NPC Patient and Family Conference Hosted by the Australian NPC Disease Foundation
June 21, 2021
From
Cyclo Therapeutics, Inc.
Via
Business Wire
Cyclo Therapeutics Commences Patient Enrollment in TransportNPC, a Pivotal Phase 3 Study Evaluating Trappsol® Cyclo™ in Niemann-Pick Type C1
June 17, 2021
From
Cyclo Therapeutics, Inc.
Via
Business Wire
Cyclo Therapeutics Announces Launch of New Website
June 15, 2021
From
Cyclo Therapeutics, Inc.
Via
Business Wire
Cyclo Therapeutics Announces Inclusion in the Russell 2000® Index
June 14, 2021
From
Cyclo Therapeutics, Inc.
Via
Business Wire
Cyclo Therapeutics to Present at the JMP Securities Life Sciences Conference
June 09, 2021
From
Cyclo Therapeutics, Inc.
Via
Business Wire
Cyclo Therapeutics to Participate in the M-Vest Virtual Conference Series: Alzheimer’s Disease Panel
May 20, 2021
From
Cyclo Therapeutics, Inc.
Via
Business Wire
Cyclo Therapeutics Provides Business Update and Reports First Quarter 2021 Financial Results
May 17, 2021
From
Cyclo Therapeutics, Inc.
Via
Business Wire
Cyclo Therapeutics Appoints Lori McKenna Gorski as Global Head of Patient Advocacy
May 11, 2021
From
Cyclo Therapeutics, Inc.
Via
Business Wire
Cyclo Therapeutics Announces Design of Pivotal Phase 3 Study Evaluating Trappsol® Cyclo™ in Niemann-Pick Type C1
April 27, 2021
From
Cyclo Therapeutics, Inc.
Via
Business Wire
Cyclo Therapeutics to Proceed with IND Filing for Phase 2 Trial Using Intravenous Trappsol® Cyclo™ in Alzheimer’s Disease
April 20, 2021
From
Cyclo Therapeutics, Inc.
Via
Business Wire
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.